1.79

2.70% -0.06

Annovis Bio Inc (ANVS)

Overview News Price History Why ANVS Down? Discussions Forecast

Annovis Bio Inc stock is traded at $1.79, with a volume of 483.26K. It is down -2.70% in the last 24 hours and up +3.45% over the past month. Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.

Previous Close:

$1.85

Open:

$1.82

24h Volume:

483.26K

Relative Volume:

0.51

Market Cap:

$76.15M

Revenue:

Net Income/Loss:

$-40.92M

P/E Ratio:

-1.0427

EPS:

-1.7167

Net Cash Flow:

$-26.53M

1W Performance:

-4.76%

1M Performance:

+3.45%

6M Performance:

-24.37%

1Y Performance:

-34.31%

1-Day Range:

$1.79

$1.85

1-Week Range:

$1.75

$1.91

52-Week Range:

$1.5407

$5.50

Annovis Bio Inc Stock (ANVS) Company Profile

Name

Annovis Bio Inc

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

484-875-3192

Address

101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA

Employee

Twitter

Next Earnings Date

2026-08-18

Latest SEC Filings

ANVS's Discussions on Twitter

Compare ANVS vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ANVS Annovis Bio Inc	1.79	78.70M	0	-40.92M	-26.53M	-1.7167
VRTX Vertex Pharmaceuticals Inc	515.31	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	806.34	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	992.59	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	215.54	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.30	39.31B	5.76B	514.49M	1.10B	4.4813

Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-10-25	Downgrade	D. Boral Capital	Buy → Hold
Oct-25-24	Upgrade	Maxim Group	Hold → Buy
Dec-29-23	Initiated	Canaccord Genuity	Buy
Jul-07-21	Reiterated	Maxim Group	Buy

Annovis Bio Inc Stock (ANVS) Latest News

Aug 16, 2026

Certain Stock Options of Annovis Bio, Inc. are subject to a Lock-Up Agreement Ending on 17-AUG-2026. - marketscreener.com

Aug 16, 2026

Aug 14, 2026

Annovis Bio (NYSE:ANVS) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat

Aug 14, 2026

Annovis Bio (ANVS) posts $32.4M loss and warns on going-concern risk - Stock Titan

Aug 14, 2026

ANVS: Net loss rose sharply as clinical trial costs surged, with cash runway only through Q4 2026 - TradingView

Aug 14, 2026

ANVS: Alzheimer's Phase 3 trial fully enrolled; R&D costs and net loss per share increased year-over-year - TradingView

Aug 14, 2026

Annovis Reports $14.8 Million Q2 Loss as Phase 3 AD Trial Fully Enrolls - Quiver Quantitative

Aug 14, 2026

Highbridge Capital (ANVS) discloses 6.1% Annovis Bio stake tied to 2.78M warrant shares - Stock Titan

Aug 14, 2026

Annovis Bio Sees Unusually Large Options Volume (NYSE:ANVS) - MarketBeat

Aug 14, 2026

Annovis Bio Q2 EPS of $(0.40) beats $(0.45) estimate - scanx.trade

Aug 14, 2026

Annovis Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 14, 2026

Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results - The Manila Times

Aug 14, 2026

Annovis expects October study to let Alzheimer’s patients continue treatment - Stock Titan

Aug 14, 2026

Aug 13, 2026